Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulocuplumab plus low-dose cytarabine in newly diagnosed acute myeloid leukemia (Phase 1/2, Japan)
jRCT2080222750Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of ulocuplumab in acute myeloid leukemia (AML) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Phase 1 primary endpoint and Phase 2 primary endpoint. Started Jan 2015; status: completed.
02
Drugs
ulocuplumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080222750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222750.